LACTOLOGY FOUNDATION

H2-receptor antagonists (ATC class A02BA) are gastric acid–suppressing drugs that are generally considered compatible with breastfeeding, with famotidine and nizatidine preferred due to lower transfer into breast milk and cimetidine and ranitidine used with somewhat greater caution. Available human data in pregnancy suggest no increase in major malformations or other serious adverse outcomes, although a slight, probably confounded increase in preterm birth has been reported.

Class definition and members

H2-receptor antagonists (A02BA) are competitive, reversible blockers of histamine H2 receptors on gastric parietal cells, reducing both basal and stimulated gastric acid secretion. They are indicated mainly for peptic ulcer disease, gastroesophageal reflux, functional dyspepsia, stress ulcer prophylaxis, and hypersecretory states such as Zollinger–Ellison syndrome.

The ATC A02BA subgroup currently includes classic H2 blockers such as cimetidine, ranitidine bismuth citrate, famotidine and nizatidine, with minor structural differences accounting for variations in potency and safety profile. All agents share the same primary pharmacological target but differ in pharmacokinetics, drug–drug interaction potential and extent of transfer into breast milk.

Mechanism of action and pharmacokinetics

All A02BA drugs competitively inhibit histamine binding at H2 receptors of gastric parietal cells, thereby suppressing acid output both in fasting state and after meals. This reduction in intragastric acidity alleviates symptoms and promotes healing of acid-related mucosal lesions in the esophagus, stomach and duodenum.

H2 antagonists are well absorbed orally and can also be administered intravenously, with relatively short elimination half-lives that limit sustained plasma exposure. They undergo varying degrees of hepatic metabolism and renal excretion, and they may reduce absorption of concomitant drugs that require an acidic gastric pH for optimal uptake.

General toxicity profile (mother)

H2 antagonists are generally well tolerated, but can cause mild adverse effects such as diarrhea, headache, malaise, flu-like symptoms, allergic reactions, and easy bruising or bleeding. Cimetidine, in particular, has been associated with antiandrogenic effects, hormonal disturbances and clinically relevant drug–drug interactions due to inhibition of hepatic cytochrome P450 isoenzymes.

Serious hepatotoxicity is rare but has been reported with ranitidine in predisposed adults, and similar concern exists in neonates with immature hepatic function. Neuropsychiatric effects (confusion, agitation) and hematologic reactions have been described, especially in older or critically ill patients, but remain uncommon at typical therapeutic doses.

Reproductive and developmental toxicity

Epidemiologic studies and pregnancy registries involving several thousand exposed pregnancies indicate no overall increase in major congenital malformations after first- or second-trimester exposure to H2 antagonists as a class. Specific analyses for ranitidine and cimetidine similarly do not show a consistent signal for teratogenicity, although isolated case reports of malformations and neonatal liver dysfunction exist.

Available data also do not support increased risks of miscarriage, intrauterine fetal death, low birth weight, or adverse neurodevelopmental outcomes, though study size limits precision. A meta-analysis suggested a modest increase in preterm delivery among women treated with H2 antagonists, but the effect is likely confounded by the underlying indication (severe reflux or hyperemesis) rather than the drug itself.

Lactation: general considerations

All H2 antagonists pass into breast milk to some extent, but infant exposure is generally low because of short half-lives and modest milk-to-plasma ratios. Specialist lactation resources and medicines information services consider the entire class compatible with breastfeeding, with no consistent reports of serious adverse effects in breastfed infants.

Nevertheless, infant hepatic and renal immaturity—particularly in preterm neonates—may increase susceptibility to drug accumulation and hepatotoxicity, prompting preference for agents with lower milk transfer and better safety documentation. For all agents, it is advisable to use the lowest effective maternal dose and to monitor vulnerable infants (especially preterm or those with comorbidities) for signs of sedation, feeding difficulties, or unusual gastrointestinal symptoms.

Individual agents and lactation safety

Cimetidine shows measurable transfer into breast milk and has documented weak antiandrogenic effects, although it is not mutagenic and has not been shown to impair sexual differentiation or development in exposed fetuses or children. Because of its higher interaction potential and hormonal effects, cimetidine is generally not preferred as first-line therapy in breastfeeding women when safer alternatives are available.

Ranitidine is one of the best-studied H2 antagonists in the context of pregnancy and lactation and has historically been labeled as compatible with breastfeeding, with caution. However, rare cases of maternal hepatotoxicity and concern about immature hepatic metabolism in preterm neonates support using it carefully in high-risk dyads or preferring other agents.

Famotidine and nizatidine achieve lower concentrations in breast milk compared with cimetidine or ranitidine, resulting in smaller relative infant doses. For this reason, these two molecules are often recommended as first-choice H2 blockers in breastfeeding women, provided they adequately control maternal symptoms.

Pregnancy risk assessment

Collectively, data from over 4,600 pregnancies exposed to H2 antagonists indicate no need for pregnancy termination or special fetal monitoring solely because of exposure to this drug class. When H2 antagonists are clinically indicated during pregnancy—for example, in severe reflux or ulcer disease—benefits of maternal symptom control usually outweigh theoretical fetal risks, especially if non-pharmacologic measures and non-systemic agents have failed.

Because proton pump inhibitors and non-systemic options such as antacids, alginates and sucralfate may be alternatives, therapeutic decisions should be individualized according to gestational age, severity of disease and response to other interventions. Clinicians should also consider potential long-term outcomes such as a possible association with childhood asthma, though current data are conflicting and likely confounded, and do not justify withholding necessary therapy.

Clinical positioning in breastfeeding women

Guidelines and expert reviews recommend a stepwise approach to reflux and dyspepsia in breastfeeding women, starting with lifestyle measures and non-systemic agents (antacids, alginates), then escalating to H2 antagonists if needed. Within the H2 class, famotidine or nizatidine are preferred due to lower breast milk transfer and favorable safety profiles, whereas ranitidine or cimetidine may be reserved for situations where they are the only available or effective options.

Available clinical experience suggests that standard therapeutic doses of H2 antagonists do not require routine laboratory monitoring in healthy term breastfed infants, although vigilance is warranted in preterm or medically complex neonates. The maternal benefit of effective reflux control is significant, as poorly controlled symptoms can impair nutrition, sleep and overall well-being, indirectly affecting breastfeeding success.

Summary of toxicology–lactology profile (A02BA)

Overall, H2-receptor antagonists in the A02BA class have a favorable toxicological profile, with mainly mild adverse effects and no strong evidence of teratogenicity or carcinogenicity at therapeutic doses. Cimetidine’s antiandrogenic and interaction potential and ranitidine’s rare hepatotoxicity merit attention, but these issues can usually be managed by agent selection and appropriate clinical monitoring.

From a lactation standpoint, all H2 antagonists are considered compatible with breastfeeding, with famotidine and nizatidine regarded as preferred options due to lower infant exposure, and ranitidine and cimetidine used when clinically justified. In high-risk infants—particularly preterm neonates with immature hepatic function—clinicians should individualize therapy, use the lowest effective doses and monitor for rare but potentially serious adverse reactions.